NBB wrote "I am wondering why it couldn't go straight to a phase 3 trial for the next 3 years"

In case you missed it in the BIO Investor Forum slide deck....they had a meeting with the FDA and have received very positive FDA feedback for design of a Phase 2b/3 registration enabling study to compare enzalutamide single agent vs. ZEN-3694+enzalutamide combo for mCRPC.....most likely blinded and randomized. So sounds like Phase 3 is around the corner. The current Phase 2 lacks an enzalutamide alone standard of care group, which is required to prove superiority.

BDAZ